Evidence map›Paper›PMID 36985197›Full record

ArticleMicroorganisms2023

CRISPR/Cas9-Mediated Multi-Locus Promoter Engineering in

Xuemei Zhang, Yan Wang, Yue Zhang, Meng Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Synthetic and systems biotechnology · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. CRISPR/Cas9-Mediated Promoter Engineering in Saccharopolyspora erythraea.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Xuemei ZhangSchool of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China.
Yan WangTianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.
Yue ZhangTianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China.ORCID 0000-0002-4383-6313
Meng WangSchool of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China.
University of Science and Technology of China · CNChinese Academy of Sciences · CNTianjin University of Science and Technology · CN

Funding

"Key Research Project" of Haihe Laboratory of Synthetic Biology and Tianjin Synthetic Biotechnology Innovation Capacity Improvement Project TSBICIP-PTJS-003 and TSBICIP-KJGG-006National Key R&D Program of China 2019YFA0905700
6 · The paper itself

Abstract

Erythromycins are a group of macrolide antibiotics produced by

Indexed as

CRISPR/Cas9erythromycinexpression fine-tuningproductionpromoter engineeringSaccharopolyspora erythraeatranscriptional level

Identifiers

PMID36985197
PMCPMC10059589
OpenAlexW4322741999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.